Cart
sales@molnova.com
Cixutumumab
CAS No. 947687-12-9
Cixutumumab( —— )
Catalog No. M37164 CAS No. 947687-12-9
Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 312 | In Stock |
|
| 10MG | 503 | In Stock |
|
| 25MG | 801 | In Stock |
|
| 50MG | 1051 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCixutumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionCixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling.
-
DescriptionCixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.
-
In VitroCixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells.Cell Viability Assay Cell Line:CHLA-9, TC-71, Rh41 cells Concentration:0.01-100 nM Incubation Time:96 h Result:Inhibited CHLA-9, TC-71and Rh41 cells growth with IC50 values of 49.31, 0.66 and 0.04 nM, respectively.
-
In VivoCixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.Animal Model:CB17SC-M scid-/- female mice (solid tumor xenografts model).Dosage:1 mg/rat Administration:Intraperitoneal injection; twice weekly for 6 weeks.Result:Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number947687-12-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.?
molnova catalog
related products
-
CPYPP
CPYPP is an inhibitor of DOCK2-Rac1 interaction. CPYPP binds to DOCK2 DHR-2 domain and inhibits the guanine nucleotide exchange factor (GEF) activity of DOCK2DHR-2 for Rac1 in a dose-dependent manner(IC50 : 22.8 μM).
-
Halopemide
Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research.
-
Neoprocurcumenol
Neoprocurcumenol is a larvicidal compound that exerts significant toxicity on mosquito larvae with LC50 and LC 90 values of 13.69 and 23.92 ppm, respectively.
